Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 26, 2026American Journal of Hematology

Clinical Implications of CD19 ‐Negative Relapse Following CD19 ‐Directed Therapy in B‐Cell Acute Lymphoblastic Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

TOTamer OthmanUniversity of California, San FranciscoVAVaibhav AgrawalCity Of Hope National Medical CenterJSJoo Y. SongCity of Hope

Discussion

Loading...

Member takes

Implication

Retrospective analysis reports poor outcomes following CD19-negative relapse in B-cell ALL, suggesting limited treatment options.

Key Points

  • This study aims to analyze the treatment patterns and outcomes of patients with CD19-negative relapse after CD19-directed therapy for B-cell acute lymphoblastic leukemia.
  • Retrospective analysis of 65 adult patients with CD19-relapse after CD19-directed therapy.
  • Analysis of mutations and treatment patterns, including blinatumomab and CAR T-cell therapy.
  • Evaluation of event-free survival (EFS) and overall survival (OS) among patients.
  • Median event-free survival was 3.1 months (95% CI, 2.5-4.5).
  • Median overall survival was 9.9 months (95% CI, 6.8-24.7).
  • Receipt of ≥2 CD19-directed therapies was linked to worse EFS (HR 2.17, p=0.03) and OS (HR 3.05, p=0.005).

Cite This Study

Othman et al. (2026) studied this question.

synapsesocial.com/papers/6a65a501d3aea3239cd7756ehttps://doi.org/10.1002/ajh.70450
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clonal evolution from B-cell acute lymphoblastic leukemia with BCR::ABL1 multilineage involvement to acute myeloid leukemia after multiple anti-CD19 chimeric antigen receptor T-cell therapy2024 · 3 citations
  2. 2Comparison of flow cytometric and immunohistochemical immunophenotyping data for diagnosis of B-cell neoplasms and classic hodgkin's lymphoma2018 · 3 citations
  3. 3CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)2015 · 118 citations
  4. 4Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma2022 · 758 citations
  5. 5CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity2016 · 440 citations